Alaunos Therapeutics, Inc.
TCRTHealthcare|Biotechnology|US
$1.74
-0.10 (-5.43%)
DCF Value
$0.33
Tangible Book / Share
$0.27
Cash / Share
$0.05
Financials
Financial Snapshot
Market Cap
$6.0M
Enterprise Value
$5.9M
Revenue (TTM)
$3.0K
Net Income (TTM)
-$4.0M
Cash & Investments
$124.0K
Net Cash
$124.0K
Free Cash Flow (TTM)
-$2.8M
Operating CF (TTM)
-$2.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$124.0K
Quarterly Burn
$681.7K
Monthly Burn
$227.2K
Est. Runway
~0.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $81.1M | $70.9M | $61.7M | $79.7M | $115.1M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M | $124.0K | |
| Operating Cash Flow | -$58.3M | -$54.7M | -$49.5M | -$40.9M | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$5.0M | -$2.9M | -$2.7M | |
| Free Cash Flow | -$58.9M | -$55.4M | -$49.9M | -$41.1M | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$5.0M | -$3.0M | -$2.8M | |
| Capital Expenditure | -$551.0K | -$737.0K | -$459.0K | -$284.0K | -$9.8M | -$3.3M | -$216.0K | -$197.0K | $0.00 | -$98.0K | -$98.0K | |
| Financing Cash Flow | -$788.0K | $45.3M | $40.3M | $59.1M | $102.1M | $25.8M | $6.4M | -$18.1M | $0.00 | $3.3M | $70.0K |
R&D Spending
R&D (TTM)
$1.6M
R&D Intensity
54833.3%
R&D Growth vs Prior
+20.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $6.4M | $146.0K | $0.00 | $0.00 | $398.0K | $2.9M | $5.0K | $10.0K | $5.0K | $3.0K | |
| R&D Expense | $157.8M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362.0K | $1.4M | $1.6M | |
| R&D % of Revenue | 2299.8% | 705.7% | 23379.5% | — | — | 12473.1% | 856.2% | 325580.0% | 3620.0% | 27260.0% | 54833.3% | |
| SG&A | $14.4M | $14.8M | $19.9M | $18.9M | $26.5M | $26.3M | $13.1M | $12.2M | $4.5M | $2.9M | $2.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $6.4M | $146.0K | $0.00 | $0.00 | $398.0K | $2.9M | $5.0K | $10.0K | $5.0K | $3.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $629.0K | $1.1M | $47.3M | $22.5M | $4.8M | $362.0K | $1.4M | $847.0K | |
| Gross Profit | $6.9M | $6.4M | $146.0K | -$629.0K | -$1.1M | -$46.9M | -$19.6M | -$4.8M | -$352.0K | -$1.4M | -$844.0K | |
| R&D | $157.8M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362.0K | $1.4M | $1.6M | |
| SG&A | $14.4M | $14.8M | $19.9M | $18.9M | $26.5M | $26.3M | $13.1M | $12.2M | $4.5M | $2.9M | $2.4M | |
| Operating Income | -$165.3M | -$53.5M | -$53.9M | -$57.9M | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M | -$4.1M | |
| Interest Expense | $0.00 | $830.0K | $0.00 | $0.00 | $0.00 | $1.2M | $3.2M | $1.9M | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M | -$4.0M | |
| Net Income | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M | -$4.0M | |
| EPS (Diluted) | -190.15 | -59.50 | -55.44 | -158.90 | -56.42 | -53.80 | -25.97 | -21.97 | -2.92 | -2.20 | -1.95 | |
| EBITDA | -$165.0M | -$53.1M | -$53.3M | -$117.2M | -$78.8M | -$75.0M | -$31.8M | -$30.9M | -$4.7M | -$4.2M | -$4.0M | |
| Shares Out. (M) | 0.87 | 0.91 | 0.96 | 1.12 | 1.40 | 1.43 | 1.45 | 1.60 | 1.60 | 1.95 | 2.43 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $81.1M | $70.9M | $61.7M | $79.7M | $115.1M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M | $124.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $104.9M | $90.8M | $84.3M | $105.5M | $130.6M | $78.8M | $53.8M | $8.3M | $2.8M | $2.0M | $666.0K | |
| Total Assets | $106.3M | $105.6M | $95.1M | $109.1M | $146.3M | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M | $1.5M | |
| Total Current Liabilities | $15.8M | $20.9M | $9.5M | $12.5M | $18.4M | $16.0M | $24.2M | $2.0M | $692.0K | $813.0K | $864.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $183.6M | $202.4M | $9.5M | $14.1M | $22.4M | $36.8M | $26.4M | $2.0M | $692.0K | $813.0K | $864.0K | |
| Stockholders' Equity | -$77.3M | -$96.8M | $85.6M | $95.0M | $124.0M | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M | $652.0K | |
| Retained Earnings | -$658.0M | -$712.4M | -$566.3M | -$684.1M | -$764.1M | -$842.9M | -$880.6M | -$915.8M | -$920.4M | -$924.6M | -$926.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$58.3M | -$54.7M | -$49.5M | -$40.9M | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$5.0M | -$2.9M | -$2.7M | |
| Capital Expenditure | -$551.0K | -$737.0K | -$459.0K | -$284.0K | -$9.8M | -$3.3M | -$216.0K | -$197.0K | $0.00 | -$98.0K | -$98.0K | |
| Free Cash Flow | -$58.9M | -$55.4M | -$49.9M | -$41.1M | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$5.0M | -$3.0M | -$2.8M | |
| Investing Cash Flow | -$551.0K | -$737.0K | -$459.0K | -$284.0K | -$9.8M | -$3.3M | -$193.0K | $1.3M | $0.00 | -$98.0K | -$98.0K | |
| Financing Cash Flow | -$788.0K | $45.3M | $40.3M | $59.1M | $102.1M | $25.8M | $6.4M | -$18.1M | $0.00 | $3.3M | $70.0K | |
| Issuance of Stock | $0.00 | $47.3M | $47.1M | $6.1M | $101.7M | $0.00 | $14.7M | $92.0K | $0.00 | $1.9M | $70.0K | |
| Repurchase of Stock | -$1.5M | -$2.1M | -$1.6M | -$653.0K | $0.00 | $0.00 | -$45.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $25.0M | -$8.3M | -$18.1M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $8.5M | $8.5M | $7.5M | $7.3M | $6.8M | $10.8M | $3.5M | $2.8M | $435.0K | $414.0K | $275.0K | |
| Net Change in Cash | -$59.7M | -$10.1M | -$9.6M | $18.0M | $35.3M | -$39.0M | -$23.1M | -$46.9M | -$5.0M | $294.0K | -$2.8M |
Dilution Tracker
Shares outstanding grew 39.4% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+39.4%
Stock Issuance (TTM)
$70.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.87 | 0.91 | 0.96 | 1.12 | 1.40 | 1.43 | 1.45 | 1.60 | 1.60 | 1.95 | 2.43 | |
| Change vs Prior % | — | 5.0% | 4.8% | 17.0% | 24.8% | 2.3% | 1.3% | 10.5% | 0.1% | 21.7% | 24.8% | |
| Stock Issuance | $0.00 | $47.3M | $47.1M | $6.1M | $101.7M | $0.00 | $14.7M | $92.0K | $0.00 | $1.9M | $70.0K | |
| Stock Repurchase | -$1.5M | -$2.1M | -$1.6M | -$653.0K | $0.00 | $0.00 | -$45.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $8.5M | $8.5M | $7.5M | $7.3M | $6.8M | $10.8M | $3.5M | $2.8M | $435.0K | $414.0K | $275.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | — | — | -11778.1% | -670.6% | -95960.0% | -3520.0% | -27160.0% | -28133.3% | |
| Operating Margin % | -2409.4% | -837.3% | -36921.9% | — | — | -19484.7% | -1201.4% | -685340.0% | -48120.0% | -84500.0% | -135266.7% | |
| Net Margin % | -2409.2% | -850.3% | -36381.5% | — | — | -19786.7% | -1291.2% | -702800.0% | -46790.0% | -83520.0% | -133666.7% | |
| EBITDA Margin % | -2405.0% | -831.5% | -36528.1% | — | — | -18835.4% | -1088.9% | -618080.0% | -46770.0% | -83380.0% | -132866.7% | |
| FCF Margin % | -858.1% | -867.2% | -34189.0% | — | — | -16279.1% | -1007.8% | -606780.0% | -49710.0% | -59340.0% | -94166.6% | |
| ROE % | 213.8% | 56.1% | -62.1% | -124.0% | -64.5% | -135.6% | -97.9% | -557.2% | -226.8% | -194.0% | -232.6% | |
| ROA % | -155.4% | -51.4% | -55.9% | -108.0% | -54.6% | -83.0% | -58.1% | -425.3% | -169.8% | -140.8% | -264.5% | |
| ROIC % | -182.6% | -63.1% | -63.0% | -59.4% | -62.4% | -88.0% | -59.9% | -543.3% | -233.3% | -196.2% | -622.4% | |
| R&D / Revenue % | 2299.8% | 705.7% | 23379.5% | — | — | 12473.1% | 856.2% | 325580.0% | 3620.0% | 27260.0% | 54833.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.4% | -6.9% | -97.7% | -100.0% | 0.0% | 0.0% | 634.2% | -99.8% | 100.0% | -50.0% | |
| Gross Profit | 58.4% | -6.9% | -97.7% | -530.8% | -79.3% | -4055.8% | 58.2% | 75.5% | 92.7% | -285.8% | |
| Operating Income | -37.6% | 67.6% | -0.8% | -7.3% | -38.9% | 3.5% | 54.7% | 2.4% | 86.0% | 12.2% | |
| Net Income | -37.6% | 67.1% | 2.2% | -121.8% | 32.1% | 1.5% | 52.1% | 6.9% | 86.7% | 10.8% | |
| EPS (Diluted) | -32.4% | 68.7% | 6.8% | -186.6% | 64.5% | 4.6% | 51.7% | 15.4% | 86.7% | 24.7% | |
| Operating Cash Flow | -583150.0% | 6.3% | 9.5% | 17.4% | -39.6% | -7.8% | 52.4% | -3.1% | 83.5% | 42.3% | |
| Free Cash Flow | -13851.7% | 5.9% | 9.9% | 17.6% | -62.4% | 3.0% | 54.5% | -3.0% | 83.6% | 40.3% | |
| R&D Expense | 47.8% | -71.4% | -24.3% | 12.3% | 37.5% | -5.8% | -49.6% | -34.9% | -97.8% | 276.5% | |
| SG&A Expense | -18.5% | 2.9% | 34.6% | -5.1% | 40.4% | -1.0% | -50.0% | -7.0% | -63.5% | -35.7% | |
| Total Assets | -30.8% | -0.7% | -10.0% | 14.8% | 34.1% | -35.2% | -31.5% | -87.3% | -66.7% | 7.7% | |
| Book Value / Share | -185.1% | -19.3% | 184.3% | -5.1% | 4.5% | -54.2% | -34.4% | -85.2% | -67.3% | -14.2% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 104.7% | 525.1% | -33.3% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 4.0% | 5.0% | 4.8% | 17.0% | 24.8% | 2.3% | 1.3% | 10.5% | 0.1% | 21.7% |
Valuation
P/E (TTM)At Loss
P/S1995.59
10Y Low / Med / High48.24 / 587.17 / 3394.19
P/B6.49
10Y Low / Med / High1.48 / 3.66 / 8.34
EV/EBITDAAt Loss
EV/Revenue1954.26
10Y Low / Med / High41.74 / 471.70 / 2181.79
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.33
Tangible Book / Share
$0.27
Cash / Share
$0.05
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -4.22 | -10.44 | -5.05 | -4.46 | -6.70 | -3.04 | -3.75 | -0.48 | -0.65 | -1.47 | -0.89 | |
| P/S Ratio | 101.68 | 88.73 | 1838.09 | 0.00 | 0.00 | 587.17 | 48.24 | 3394.19 | 305.84 | 1258.64 | 1995.59 | |
| P/B Ratio | -9.02 | -5.86 | 3.14 | 8.34 | 4.26 | 4.03 | 3.66 | 2.69 | 1.48 | 2.92 | 6.49 | |
| EV/EBITDA | -3.74 | -9.34 | -3.87 | -6.11 | -5.30 | -2.50 | -3.83 | -0.35 | -0.42 | -1.18 | -1.47 | |
| EV/Revenue | 89.86 | 77.63 | 1415.29 | 0.00 | 0.00 | 471.70 | 41.74 | 2181.79 | 196.74 | 981.64 | 1954.26 |
Analyst Estimates & Quality
Altman Z-Score
-860.41
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $87.5M | $220.4M |
| Net Income | -$40.9M | -$35.1M |
| EPS | $-21.00 | $-18.00 |
| # Analysts (EPS) | 1 | 1 |